



University of Southern Denmark

Association Between Statin Use and Intracerebral Hemorrhage Location: A Nested Case-Control Registry Study

Boe, Nils Jensen; Munk Hald, Stine; Jensen, Mie Micheelsen; Bojsen, Jonas Asgaard; Talal Elhakim, Mohammad; Florisson, Sandra; Saleh, Alisa; Clausen, Anne; Möller, Sören; Severin Gråe Harbo, Frederik; Graumann, Ole; Hallas, Jesper; García Rodríguez, Luis Alberto; Salman, Rustam Al-Shahi; Goldstein, Larry B; Gaist, David

Published in:
Neurology

DOI:
10.1212/WNL.0000000000201664

Publication date:
2023

Document version:
Accepted manuscript

Citation for pulished version (APA):

Boe, N. J., Munk Hald, S., Jensen, M. M., Bojsen, J. A., Talal Elhakim, M., Florisson, S., Saleh, A., Clausen, A., Möller, S., Severin Gråe Harbo, F., Graumann, O., Hallas, J., García Rodríguez, L. A., Salman, R. A.-S., Goldstein, L. B., & Gaist, D. (2023). Association Between Statin Use and Intracerebral Hemorrhage Location: A Nested Case-Control Registry Study. *Neurology*, *100*(10), e1048-e1061.
<https://doi.org/10.1212/WNL.0000000000201664>

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use

This work is brought to you by the University of Southern Denmark.
Unless otherwise specified it has been shared according to the terms for self-archiving.
If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.
Please direct all enquiries to puresupport@bib.sdu.dk

Neurology Publish Ahead of Print

DOI: 10.1212/WNL.000000000201664

Association Between Statin Use and Intracerebral Hemorrhage Location: A Nested Case-Control Registry Study

Author(s):

Nils Jensen Boe, MD¹; Stine Munk Hald, MD¹; Mie Micheelsen Jensen, MD¹; Jonas Asgaard Bojsen, MD²; Mohammad Talal Elhakim, MD²; Sandra Florisson, MD¹; Alisa Saleh¹; Anne Clausen, MSc³; Sören Möller, PhD^{3,4}; Frederik Severin Gråe Harbo, MD²; Ole Graumann, PhD²; Jesper Hallas, DrMedSci⁵; Luis Alberto García Rodríguez, MD⁶; Rustam Al-Shahi Salman, MD PhD⁷; Larry B. Goldstein, MD⁸; David Gaist, PhD¹

Corresponding Author:

David Gaist, dgaist@health.sdu.dk

Affiliation Information for All Authors: 1. Research Unit for Neurology, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark; 2. Department of Radiology, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark; 3. Open Patient Data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark; 4. Department of Clinical Research, University of Southern Denmark, Odense, Denmark; 5. Department of Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark; 6. Centro Españõl Investigación Farmacoepidemiológica, Madrid, Spain; 7. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom; 8. Department of Neurology and Kentucky Neuroscience Institute, University of Kentucky, Lexington, USA

Equal Author Contribution:

Neurology[®] Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.

Contributions:

Nils Jensen Boe: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

Stine Munk Hald: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

Mie Micheelsen Jensen: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

Jonas Asgaard Bojsen: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

Mohammad Talal Elhakim: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

Sandra Florisson: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

Alisa Saleh: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

Anne Clausen: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

Sören Möller: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

Frederik Severin Gråe Harbo: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

Ole Graumann: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

Jesper Hallas: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

Luis Alberto García Rodríguez: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

Rustam Al-Shahi Salman: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

Larry B. Goldstein: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

David Gaist: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data; Additional contributions: Funding Supervision

Figure Count:

0

Table Count:

7

Search Terms:

[2] All Cerebrovascular disease/Stroke, [7] Intracerebral hemorrhage, [12] Stroke prevention, hydroxymethylglutaryl-CoA Reductase inhibitors, statins

Acknowledgment:**Study Funding:**

The project received funding from the Novo Nordisk Foundation (grant no. NNF20OC0064637; Dr Gaist). The funding organization had no role in the design of the study or the collection, analysis, and the interpretation of the data, or the interpretation of data and manuscript writing.

Disclosures:

N.J. Boe, S.M. Hald, M.M. Jensen, J.A. Bojsen, M.T. Elhakim, S. Florrison, F.S.G. Harbo, O. Graumann, S. Möller, A. Clausen, and A. Saleh report no conflicts of interest. L.A. García Rodríguez works for CEIFE, which received research grants from Bayer AG for other research projects; and has also served as an advisory board member for Bayer AG. J. Hallas participated in projects outside the submitted work that were funded by AstraZeneca and Pfizer with money paid to his employer (no personal compensation). R. Al-Shahi Salman is an unpaid member of the Trial Steering Committee for the Statins In Intracerebral Hemorrhage (SATURN) trial (NCT03936361). L.B. Goldstein was a member of the Steering Committee for the Pfizer-supported SPARCL trial. D. Gaist received speaker honorarium from Bristol-Myers Squibb and Pfizer unrelated to this work.

Preprint DOI:**Received Date:**

2022-08-29

Accepted Date:

2022-10-24

Handling Editor Statement:

Submitted and externally peer reviewed. The handling editor was José Merino, MD, MPhil, FAAN.

ABSTRACT**Background**

A causal relationship between statin use and intracerebral hemorrhage (ICH) is uncertain. We hypothesized that an association between long-term statin exposure and ICH risk might vary for different ICH locations.

Methods

We conducted this analysis using linked Danish nationwide registries. Within the Southern Denmark Region (population 1.2 million), we identified all first-ever cases of ICH between 2009-2018 in persons ages ≥ 55 years. Patients with medical record verified diagnoses were classified as having a lobar or non-lobar ICH and matched for age, sex, and calendar year to general population controls. We used a nationwide prescription registry to ascertain prior statin and other medication use that we classified for recency, duration, and intensity. Using conditional logistic regression

adjusted for potential confounders, we calculated adjusted odds ratios (aORs) and corresponding 95% Confidence Intervals (CIs) for the risk of lobar and non-lobar ICH.

Results

We identified 989 patients with lobar ICH (52.2% women, mean age 76.3-years) who we matched to 39,500 controls, and 1,175 patients with non-lobar ICH (46.5% women, mean age 75.1-years) who we matched to 46,755 controls. Current statin use was associated with a lower risk of lobar (aOR 0.83; 95%CI, 0.70-0.98) and non-lobar ICH (aOR 0.84; 95%CI, 0.72-0.98). Longer duration of statin use was also associated with lower risk of lobar (<1 year: aOR 0.89; 95%CI, 0.69-1.14; ≥ 1 year to <5 years aOR 0.89; 95%CI 0.73-1.09; ≥ 5 years aOR 0.67; 95%CI, 0.51-0.87; p for trend 0.040) and non-lobar ICH (<1 year: aOR 1.00; 95%CI, 0.80-1.25; ≥ 1 year to <5 years aOR 0.88; 95%CI 0.73-1.06; ≥ 5 years aOR 0.62; 95%CI, 0.48-0.80; p for trend <0.001). Estimates stratified by statin intensity were similar to the main estimates for low-medium intensity therapy (lobar aOR 0.82; non-lobar aOR 0.84); the association with high intensity therapy was neutral.

Discussion

We found that statin use was associated with a lower risk of ICH, particularly with longer treatment duration. This association did not vary by hematoma location.

INTRODUCTION

HMG-CoA reductase inhibitors (statins) effectively reduce the occurrence of recurrent ischemic stroke and other cardiovascular events in high risk populations.¹ An individual patient data metaanalysis of statin trials² and exploratory analyses of data from the Stroke Prevention by Aggressive Reductions in Cholesterol Levels (SPARCL) trial³ and the Heart Protection Study⁴ (HPS), however, raised concerns of an increased risk of ICH among statin users with a history of stroke. The results of subsequent observational studies, including four meta-analyses,⁵⁻⁸ focusing on patients both with⁹⁻¹³ and without^{14,15} prior stroke are inconsistent although most found no increase in bleeding. Furthermore, more recent studies that assessed the effects of intensity of treatment,¹⁶ duration-response relationships,^{15,17} or both¹⁸ found a lower risk of ICH among statin users and that the risk was inversely associated with the duration and intensity of statin treatment.

There are few data assessing the association between statin use and the location of ICH.¹⁹⁻²² Parenchymal ICH can be lobar (~35%) or deep (non-lobar, ~35%) in part reflecting differing underlying pathologies. Cerebral amyloid angiopathy (CAA) is associated with lobar but not non-lobar ICH.²³ Arteriolosclerosis, which is strongly associated with hypertension, is a common histological finding in ICH regardless of hemorrhage location.²⁴ In a population-based study, histologically verified CAA was present in 58% of patients with a lobar ICH, but the majority also had evidence of arteriolosclerosis with only 13% having isolated CAA pathology.²⁴ Whether differences in the underlying pathophysiology of lobar vs non-lobar ICH differentially affect the relationship between statin use and ICH risk has only been assessed in few population-based studies.^{16,22,25,26} These studies did not assess the relationship between the duration of statin use with ICH location.

We hypothesized that statin use is associated with a lower overall risk of ICH but that the magnitude of the association varies by ICH mechanism, having a greater benefit in reducing the risk of non-lobar ICH vs lobar ICH, reflecting a more pronounced statin effect on arteriosclerosis compared with amyloid angiopathy. To explore this hypothesis, we conducted a case-control study in which we classified hemorrhage location in all patients in a Danish region with incident ICH and compared their prior long-term use of statins with general population controls. Statin exposure for cases and controls were obtained from a prospective registry of dispensed prescriptions with full coverage of the source population for the prior 25-years.

ACCEPTED

METHODS

Design

We conducted a population-based nested case-control study within the Region of Southern Denmark (RSD) based on nationwide Danish registry data.^{27–30} Data were linked across registries using the unique 10-digit personal identifier assigned to all residents at birth or upon immigration.³⁰

Setting and Data Sources

Health care is tax-financed and free of personal charge to all residents of Denmark. Patients suspected of having a stroke are evaluated as medical emergencies with organized pathways including rapid access to neuroimaging and subsequent admission or transfer to stroke units for specialized care. The RSD (population 1.2 million), one of the five regions in the country, includes 5 stroke units and a single neurosurgical department at a university hospital and is representative of the Danish population regarding sociodemographic and health related characteristics.³¹

Standard protocol approvals, registration, and patient consents

The study was approved by the Region of Southern Denmark and informed consent was waived. Data were pseudonymized.³²

Data availability statement

Danish law prohibits the authors from sharing or granting access to the data used for this study.

Source population

The source population were all persons over age 55-years residing in the RSD between 2009-2018. The Patient Registry data for 2019-2022 have only recently been released for research, which limited the inclusion of later data for this analysis. We chose the patient age range as it is one of the modified Boston criteria for CAA³³ and because younger people are less likely to be treated with statins.

Cases

We identified cases *ad hoc*, as previously described.³⁴ In brief, we used population-based sources to trace all individuals in the RSD in the study period with a first-ever diagnosis of spontaneous ICH (s-ICH; patients having a traumatic ICH or an ICH related to aneurysmal SAH, vascular malformations, or tumors were excluded). The s-ICH diagnosis was verified by physicians who also classified the location of the hemorrhage based on discharge summaries and brain imaging reports in accordance with a previously validated method.³⁵ We assigned the index date as the date of the ICH, if established as part of the verification process and alternatively as the date of hospital admission. We linked the *ad hoc* collected s-ICH data with prospectively collected information on all residents of the RSD available from four nationwide data sources (i.e., the Danish Civil Registration System³⁰, the Danish National Patient Registry²⁹ (Patient Registry), the Danish Stroke Registry²⁷ (Stroke Registry), and the Danish National Prescription Registry²⁸ (Prescription Registry)).

Based on slightly modified criteria used in a previous population-based study,³⁶ we classified ICH location as non-lobar if the patient had a single infratentorial ICH (located in the brain stem or cerebellum), a single supratentorial deep ICH (located in the basal ganglia, internal or external capsule, or thalamus), or multiple ICHs in solely non-lobar locations (either supratentorial

deep, or infratentorial); all other ICHs were classified as lobar. We subclassified non-lobar hemorrhages as ‘deep’ and ‘cerebellar’ (a location reported to be rarely associated with CAA³⁷). We considered deep ICH as the group most likely being hypertension-related³⁸ and due to small vessel disease (SVD). We included isolated intraventricular hemorrhages (IVH), which can be related to SVD,³⁹ in overall analyses of ICH but excluded them from location-specific analyses.

Controls

We sampled the Danish Civil Registration System³⁰ to identify 40 controls without ICH from the source population for each case. Using risk-set sampling, we matched controls by birth year and sex to their index case and assigned an index date identical to the index date of their corresponding case. Cases were eligible to be selected as controls before their first-ever s-ICH. This design ensures that the odds ratio (OR) is an unbiased estimate of the incidence rate ratio and enables the calculation of absolute rate differences. We retrieved nationwide data on controls from the same registry sources as for cases (see above).

Exposure to statins

During the study period simvastatin, lovastatin, pravastatin, fluvastatin, atorvastatin, and rosuvastatin were available in Denmark for clinical use (cerivastatin was withdrawn from the Danish market in 2001). Exposure to any of these statins for s-ICH cases and controls up to the index date was determined based on prescription registry data (codes in eTable 1 in the Supplement).

Based on the most recent episode of statin use before the index date, and as in a previous study by our group,¹⁸ statin exposure was classified as: *current use* (prescription supply covered the index date, or ended within 30 days of index date); *recent use* (prescription supply ended 31-90

days before index date); *past use* (prescription supply ended 91-365 days before index date); and *non-use* (no recorded prescription before index date, or most recent prescription ended more than 365-days before the index date). We based the length of a prescription on the number of tablets dispensed (assuming a posology of once a day). A statin treatment episode comprised the length of consecutive prescriptions allowing for gaps between prescriptions of 60-days or less. We assessed potential duration-response relationships in relation with ICH location. For this analysis, we classified the duration of statin current use into the following categories: < 1; ≥ 1 to < 5; ≥ 5 years. Duration was based on the most recent episode of statin treatment before index date. We focused on duration of the most recent episode of current use of statins as a previous Danish nationwide study we conducted found that ICH risk was only associated with the duration of current use of statins with null associations for past statin use.¹⁸

We classified intensity of statin therapy based on the 2013 ACC/AHA guidelines⁴⁰ as high intensity (atorvastatin 40-80mg/day; rosuvastatin 20-40 mg/day; simvastatin 80 mg/day), moderate intensity (atorvastatin 10-20mg/day; rosuvastatin 5-10 mg/day; simvastatin 20-40mg/day; pravastatin 40-80 mg/day; lovastatin 40 mg/day), or low intensity (simvastatin 10mg/day; pravastatin 10-20mg/day; lovastatin 20mg/day; fluvastatin 20-40mg/day). Simvastatin 80mg/day was not included in ACC/AHA guidelines due to a high risk of adverse-effects;⁴⁰ however, we included this dose in the high intensity category as there was some use of that intensity in our population. We used the maximum tablet strength prescribed during the most recent episode of statin treatment assuming a one tablet per day use for this classification, as information on the physician ordered dose was not available in the Prescription Registry. Further details on classification of exposure to statins and other medications are provided in the eMethods in the Supplement.

Supplementary analyses

We also retrieved data on vital status from the Danish Civil Registry from which we identified patients with ICH who died within 30-days of the index date (fatal ICH). Patients with large hemorrhages for whom location could not be classified were not included in the main analyses but were assessed separately in a subanalysis.

To assess the effect of newly beginning a statin on ICH risk (i.e., the effect in new users⁴¹), we defined new users among cases and controls as those having no use of statins in 1995, the year the Prescription Registry became operational, and having a single episode of statin use recorded between 1996 and up to their index date (i.e., excluding those who started, stopped, and restarted statins during the period beginning in 1996).

We repeated the main analyses using cases only and comparing statin exposure for non-lobar vs lobar ICH. This analysis included the same confounders as the main analysis in addition to age, sex, and calendar time. This design was chosen to assess potential location-specific statin associations.

Brain CT-scan sub-study

We primarily used discharge records and brain scan reports to verify the diagnosis of s-ICH and to classify hematoma location. Although this method has the advantage of reflecting clinical routine, it could result in bias (e.g., radiologists were aware of clinical data, which could influence their evaluation of brain scans), and misclassification of hematoma location (e.g., either due to location not being mentioned in brain report or due to less accurate descriptions, possibly more so for large hematomas (e.g., “large supratentorial ICH”). Therefore, in a sub-study index CTs of 1,060 patients were evaluated for hematoma location (using CHARTS⁴²), hematoma volume (using ABC/2⁴³), hematoma intraventricular extension (using Graeb score⁴⁴), and evidence of small vessel

disease (i.e., presence of white matter lucencies (using van Swieten⁴⁵), or lacunar infarct sequelae) masked to clinical data (eMethods, eFigure 1 in the Supplement). We repeated the main analyses based on the data available from this sub-study and using the above outlined classifications for overall s-ICH and by hematoma location.

Covariates

We obtained data on potential confounders, proxies for confounders, and risk factors based on information retrieved from Patient Registry, Stroke Registry and Prescription Registry for both incident s-ICH cases and controls (eTable 1, eMethods in the Supplement).

Statistical analysis

We performed descriptive analyses with categorical data presented using frequency counts and percentages, and continuous data using means and standard deviation (SD). We conducted nested case-control analyses using conditional logistic regression to calculate ORs as a measure of the risk of s-ICH (overall and by location) associated with use of statins (vs. non-use), adjusted for the following covariates: history of chronic obstructive pulmonary disease (as a marker of smoking), disorders indicative of high alcohol consumption, hypertension, history of ischemic stroke, diabetes, chronic hepatic disease, chronic kidney disease, heart failure, ischemic heart disease, peripheral artery disease (PAD), cancer, coagulopathy, and current use of drugs with antihypertensive effects (loop-diuretics, non-loop diuretics, beta-blockers, calcium channel blockers, ACE inhibitors, and angiotensin II receptor blockers), antiplatelet drugs, anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), selective serotonin reuptake inhibitors (SSRIs), or proton pump inhibitors (PPIs), hormone replacement therapy, or oral corticosteroid drugs. We

chose covariates for inclusion in the model based on current knowledge regarding potential confounders and risk factors for ICH.

Our main analysis focused on the risk of ICH associated with long-term use (≥ 5 -years) of statins. We performed analyses by duration of current use of statins, intensity of treatment (overall and within strata of duration, i.e., < 5 vs ≥ 5 years). We investigated the presence of potential effect measure modification of age (classified as 55-74, ≥ 75 years; in separate analysis), sex, concurrent use of antithrombotic drugs, concurrent use of drugs with antihypertensive properties, and by history of ischemic stroke (to support comparability with a prior report that excluded patients with a history of any type of stroke in the control group²²). Analyses of effect modifications by the indicated medications and history of ischemic stroke were performed using unconditional logistic regression (i.e., without matching and with inclusion of the original matching variables in the multivariable model) and differences in strength of association between subgroups were evaluated using the 2-sample Wald test. We also conducted main analyses stratified into fatal and non-fatal ICH using their respective matched controls. To ensure that our results were not subject to prevalent user bias, we also performed ‘new user’ analyses.⁴¹ As above, we repeated the main analyses based on cases only (i.e., comparing non-lobar vs lobar (reference), and deep vs lobar (reference)). Dose-response trends in associations between drug use duration and ICH risk were tested using the duration in days as an explanatory variable in the regression. We calculated the E-values for the main results as a measure of the potential impact of unmeasured confounding.⁴⁶ The E-value is the minimum strength of association that an unmeasured confounder would need to have with both the exposure and outcome to fully explain the observed association. With higher values, the observed association is less likely to be explained by unmeasured confounding.

For the brain CT sub-study, we performed descriptive analyses of demographic, comorbidity, medication, and radiological (e.g., hematoma volume, Graeb-score, etc.)

characteristics by hematoma location and statin exposure. We repeated the main analysis of the association of duration of current statin use with overall s-ICH and by location (lobar vs deep, lobar-all vs deep-all, respectively), adjusting for confounding with the same covariates as for the main analysis.

RESULTS

After cross-linking the Stroke Registry and Patient Registry, we identified 4,621 patients with codes compatible with ICH in the study period. We identified discharge summaries and brain scan reports for 4,430 (95.9%) patients, and based primarily on this information, we verified the diagnosis of s-ICH in 2,819 cases (eFigure 1 in the Supplement). After exclusion of those younger than age 55-years, our sample included 2,519 cases with s-ICH. Of these, 989 (39.3%) were classified as lobar ICH (52.2% women, mean age 76.3 years) and 1,175 (46.6%) as non-lobar ICH (46.5% women, mean age 75.1 years). A further 275 (10.9%) were large ICHs unclassifiable with respect to location, 46 (1.8%) had isolated IVH, and 34 (1.3%) were unclassifiable due to missing information. Compared with their controls, lobar ICH patients more frequently had a history of previous ischemic stroke, chronic hepatic disease, congestive heart failure, atrial fibrillation, venous thromboembolism, mechanical heart valve, gastrointestinal bleed, coagulopathy, previous cancer, and disorders indicative of high alcohol intake (Table 1). These conditions (except congestive heart disease and previous cancer) were also more frequent in patients with a non-lobar ICH, who in addition had a higher prevalence of hypertension, peripheral arterial disease, and ischemic heart disease. Compared with their controls, lobar and non-lobar ICH cases had more frequently used anticoagulants, platelet inhibitors, and selective serotonin reuptake inhibitors. In addition, non-lobar ICH cases had more frequent preadmission use of non-steroidal anti-inflammatory drugs and proton pump inhibitors (Table 1). History of previous disorders and preadmission drug use in non-

lobar cases subclassified into ‘deep’ and ‘cerebellar’ were similar to non-lobar cases (eTable 2 in the Supplement); however, there were stronger associations with preadmission use of oral anticoagulants among those with cerebellar ICH. This was also true for large unclassifiable ICH (eTable 2).

Current use of statins was associated with a lower risk of ICH overall (adjusted OR [aOR] 0.83; 95%CI, 0.75-0.92) (Table 2), a risk that was similar for lobar (aOR 0.83; 95%CI, 0.70-0.98) and non-lobar ICH (aOR 0.84; 95%CI, 0.72-0.98) (Table 3). A longer duration of statin use was also associated with a lower risk of ICH that was similar for lobar (aOR 0.89; 95%CI, 0.69-1.14 for <1 year to aOR 0.67; 95%CI, 0.51-0.87 for use ≥ 5 years; p for trend 0.040) and non-lobar ICH (aOR 1.00; 95%CI, 0.80-1.25 for <1 year to aOR 0.62; 95%CI 0.48-0.80 for ≥ 5 years; p for trend <0.001) (Table 3). This duration response relationship was also present within strata of low-medium intensity and high intensity statin use, albeit based on small numbers (Table 3). Estimates stratified only by intensity of therapy were similar to the main estimates for low-medium intensity therapy (lobar aOR 0.82; non-lobar aOR 0.84) whereas the associations for high intensity therapy was neutral (lobar aOR 1.06; non-lobar aOR 1.02) (Table 3). Similar results were found among new users (eTable 3 in the Supplement) and analyses restricted to deep ICH cases and their controls (eTable 4). In analyses restricted to patients with ICH, there was no difference in ICH location based on duration of statin use (Table 4). E-values (Tables 2 and 3) were almost consistently above 2.5 for long-term exposure (≥ 5 years) and lower than 2.5 for short-term (<5 years) or indefinite (e.g. “current”) exposure.

The duration response relationship was present within subgroups defined by sex, age, and 30-day fatality of cases (eTables 5–7 in the Supplement); however, in subgroups defined by concurrent use of other medications, the statin treatment duration response relationship was only found in those treated with antihypertensive drugs (Table 5) and those not treated with oral

anticoagulants (Table 6) whereas the relationship with antiplatelet drug use was less clear (Table 6). The duration response relationship was present within subgroups defined by history of prior ischemic stroke (Table 7).

Brain CT sub-study results

We included 467 lobar and 572 non-lobar ICH cases with characteristics similar to those included in the main study in the brain CT sub-study (eTable 8 in the Supplement). As expected,^{47,48} compared with lobar ICH, hematoma volumes were larger and intraventricular expansion more frequent in cases with non-lobar ICH; lacunar infarct sequelae were also more frequent in lobar cases. Total and LDL-cholesterol values were similar in lobar and non-lobar cases as were renal function estimates (eGFR) (eTable 8). We found duration response relationships similar to those found in the entire dataset in case-control (eTable 9) and case-only (eTables 10–11) sub-study analyses.

DISCUSSION

In this case-control study with 989 patients with lobar ICH and 1,175 patients with non-lobar ICH, we found that statin treatment was associated with a lower risk of both lobar and non-lobar ICH. Longer duration of treatment was also associated with lower ICH risk that was similar for lobar and non-lobar locations.

Our findings regarding a lower risk of ICH in association with statin use and long-term therapy with statins are consistent with results of recent observational studies.^{15,17,18} Our findings, however, did not support our hypothesis that there would be a greater benefit in reducing the risk of non-lobar ICH vs lobar ICH, as we found that the strength of the association between statin use and lower risk of lobar ICH was similar to that found for non-lobar ICH. Of note, similarity in the

location-specific risks of lobar and non-lobar ICH was also found in a sub-analysis using a case-only approach and was robust to use of an unbiased method of ICH location ascertainment (i.e., sub-study with review of original brain scans according to CHARTS⁴² masked to clinical data). Our results on statin use and similar location-specific ICH risks could be explained by isolated CAA being uncommon in lobar ICH in unselected samples (i.e., ~13% according to a population-based study with histological confirmation²⁴). Although lobar ICH is often (~58%) associated with underlying CAA, this amyloid deposition disorder most frequently coexists with arteriolosclerosis,²⁴ a condition, which benefits from statin treatment. Our findings are consistent with those reported in a cohort study from Israel and a large case-control study from Italy.^{16,26} A multicenter study from the US, however, reported a lower risk of non-lobar (OR 0.43; 95%CI, 0.29-0.63) compared to lobar ICH (OR 0.73; 95%CI, 0.45-1.19) with statin use.²⁵ A nested case-control analysis of data from the Framingham Heart Study found a higher risk of lobar (OR 4.07; 95%CI, 1.16-14.21) but not non-lobar ICH (OR 0.99; 95%CI, 0.29-3.38) with statin use; these estimates, however, were based on a small sample (e.g., only 21 non-lobar cases (7 statin exposed) and 20 lobar cases (5 exposed)).²² Although methodological differences between studies limit direct comparisons, we found that the larger studies, including our own, reflect little or no variability in the association between statin use and the location of the hematoma in patients with an ICH.

Our findings indicate a possible effect modification of the association between statin use and risk of ICH in subgroups defined by concurrent use of antihypertensive medications or oral anticoagulants. We found that lower ICH risk was restricted to patients receiving both statins and concurrent antihypertensive drugs. Conversely, in analyses of oral anticoagulant co-medications, only patients who were not concurrently on anticoagulants had a lower risk of ICH in association with statin use. These results could represent true effects (e.g., that a causal yet weak beneficial effect of statins is moderated by stronger effects of e.g., untreated hypertension, or the use of

anticoagulants). At least for concurrent use of antihypertensive drugs, however, spurious effects need to be considered such as healthy adherer bias,⁴⁹ which may be present in statin treated patients overall and possibly more so in those adhering to more than one chronic medication regimen. Also, lack of concurrent treatment with antihypertensives could be a marker for physicians who provide less optimal preventive treatment to their patients. The observational nature of our study does not allow us to determine to extent to which associations are causal.

Strengths of our study include the inclusion of all verified cases of spontaneous ICH in a defined population in 2009-2018.^{34,35} Our unselected cohort reflects current trends in preventive medication use and stroke diagnostic evaluation. Our use of registries, which hold data prospectively collected over decades, eliminated recall bias. By using the Civil Registration System, we could identify all residents of Southern Denmark in the study period and thereby select true general population controls.

Our study also has limitations. In a previous nationwide study with no information on hematoma location, we found that longer duration of statin treatment was associated with lower risk of ICH within strata of therapeutic intensity but therapeutic intensity *per se* (i.e., unstratified by duration of statin use) was not associated with a lower risk of ICH.¹⁸ Our study is underpowered for assessing associations of intensity of statin treatment and ICH risk, but our point estimates are indicative of effects similar to those found in the nationwide study. In the main analyses we verified diagnoses based on partial medical records (i.e., discharge summaries and brain scan reports), which could raise concerns regarding diagnostic accuracy. The sub-study with masked re-evaluation of index brain scans using CHARTS⁴², however, provided results similar to our main analyses, which should alleviate concerns on our method of classifying hematoma location in the main analysis. We lacked data on education and income or other markers of socioeconomic status (SES); however, in Denmark health care is provided free of individual charge and drug costs are

covered to a variable degree (depending on a patient's total health expenditure the previous year), factors which reduce the impact of SES. Further, in previous analyses, addition of information on education and income to a model similar to the one used in this study had very little effect on ICH risk estimates.⁵⁰ We lacked data on certain potentially important confounders (e.g., blood pressure measurements), had only partial data on others (e.g., cholesterol levels only available for cases in sub-study), and needed to use proxies for smoking and alcohol. As our E-value analyses suggest, unmeasured confounding could explain some of our findings, but would have to be fairly strong to account for the longer (≥ 5 years) statin treatment duration results. The available data did not include a measure of cognitive impairment, which can be caused by CAA, and we were unable to assess whether this might be an effect modifier for the association of statin use with ICH location. Finally, our results, may not be generalizable to other populations, as the Danish population is of mainly European ancestry. Despite these caveats, we conclude that our results indicate that statin use and prolonged statin use are associated with a lower risk of spontaneous ICH that is not location specific.

<http://links.lww.com/WNL/C492>

REFERENCES

1. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2014;45(7):2160-2236. doi:10.1161/STR.0000000000000024
2. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. *The Lancet*. 2015;385(9976):1397-1405. doi:10.1016/S0140-6736(14)61368-4

3. Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. *Neurology*. 2008;70(24 Pt 2):2364-2370. doi:10.1212/01.wnl.0000296277.63350.77
4. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. *Lancet Lond Engl*. 2004;363(9411):757-767. doi:10.1016/S0140-6736(04)15690-0
5. Hackam DG, Woodward M, Newby LK, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. *Circulation*. 2011;124(20):2233-2242. doi:10.1161/CIRCULATIONAHA.111.055269
6. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. *Stroke*. 2012;43(8):2149-2156. doi:10.1161/STROKEAHA.112.655894
7. Ziff OJ, Banerjee G, Ambler G, Werring DJ. Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry*. 2019;90(1):75-83. doi:10.1136/jnnp-2018-318483
8. Sanz-Cuesta BE, Saver JL. Lipid-Lowering Therapy and Hemorrhagic Stroke Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors. *Stroke*. 2021;52(10):3142-3150. doi:10.1161/STROKEAHA.121.034576
9. FitzMaurice E, Wendell L, Snider R, et al. Effect of statins on intracerebral hemorrhage outcome and recurrence. *Stroke*. 2008;39(7):2151-2154. doi:10.1161/STROKEAHA.107.508861
10. Hackam DG, Austin PC, Huang A, et al. Statins and intracerebral hemorrhage: a retrospective cohort study. *Arch Neurol*. 2012;69(1):39-45. doi:10.1001/archneurol.2011.228
11. Chen PS, Cheng CL, Chang YC, Kao Yang YH, Yeh PS, Li YH. Early statin therapy in patients with acute intracerebral hemorrhage without prior statin use. *Eur J Neurol*. 2015;22(5):773-780. doi:10.1111/ene.12649
12. Gaist D, Goldstein LB, Cea Soriano L, García Rodríguez LA. Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack. *Stroke*. 2017;48(12):3245-3251. doi:10.1161/STROKEAHA.117.019141
13. Ribe AR, Vestergaard CH, Vestergaard M, et al. Statins and Risk of Intracerebral Hemorrhage in Individuals With a History of Stroke. *Stroke*. 2020;51(4):1111-1119. doi:10.1161/STROKEAHA.119.027301
14. Åsberg S, Eriksson M. Statin therapy and the risk of intracerebral haemorrhage: a nationwide observational study. *Int J Stroke Off J Int Stroke Soc*. 2015;10 Suppl A100:46-49. doi:10.1111/ijss.12539

15. Ribe AR, Vestergaard CH, Vestergaard M, et al. Statins and Risk of Intracerebral Haemorrhage in a Stroke-Free Population: A Nationwide Danish Propensity Score Matched Cohort Study. *EClinicalMedicine*. 2019;8:78-84. doi:10.1016/j.eclinm.2019.02.007
16. Saliba W, Rennert HS, Barnett-Griness O, et al. Association of statin use with spontaneous intracerebral hemorrhage: A cohort study. *Neurology*. 2018;91(5):e400-e409. doi:10.1212/WNL.0000000000005907
17. Jung M, Lee S. Effects of Statin Therapy on the Risk of Intracerebral Hemorrhage in Korean Patients with Hyperlipidemia. *Pharmacotherapy*. 2019;39(2):129-139. doi:10.1002/phar.2211
18. Rudolph DA, Hald SM, García Rodríguez LA, et al. Association of Long-term Statin Use With the Risk of Intracerebral Hemorrhage: A Danish Nationwide Case-Control Study. *Neurology*. 2022;99(7):e711-e719. doi:10.1212/WNL.00000000000200713
19. Woo D, Sauerbeck LR, Kissela BM, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. *Stroke*. 2002;33(5):1190-1195.
20. Haussen DC, Henninger N, Kumar S, Selim M. Statin use and microbleeds in patients with spontaneous intracerebral hemorrhage. *Stroke*. 2012;43(10):2677-2681. doi:10.1161/STROKEAHA.112.657486
21. Romero JR, Preis SR, Beiser A, et al. Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study. *Stroke*. 2014;45(5):1492-1494. doi:10.1161/STROKEAHA.114.004130
22. Lioutas VA, Beiser AS, Aparicio HJ, et al. Assessment of Incidence and Risk Factors of Intracerebral Hemorrhage Among Participants in the Framingham Heart Study Between 1948 and 2016. *JAMA Neurol*. 2020;77(10):1252-1260. doi:10.1001/jamaneurol.2020.1512
23. Samarasekera N, Smith C, Al-Shahi Salman R. The association between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry*. 2012;83(3):275-281. doi:10.1136/jnnp-2011-300371
24. Rodrigues MA, Samarasekera N, Lerpiniere C, et al. The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. *Lancet Neurol*. 2018;17(3):232-240. doi:10.1016/S1474-4422(18)30006-1
25. Martini SR, Flaherty ML, Brown WM, et al. Risk factors for intracerebral hemorrhage differ according to hemorrhage location. *Neurology*. 2012;79(23):2275-2282. doi:10.1212/WNL.0b013e318276896f
26. Pezzini A, Grassi M, Iacoviello L, et al. Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy). *J Neurol Neurosurg Psychiatry*. 2016;87(9):924-929. doi:10.1136/jnnp-2015-312736

27. Johnsen SP, Ingeman A, Hundborg HH, Schaarup SZ, Gyllenborg J. The Danish Stroke Registry. *Clin Epidemiol*. 2016;8:697-702. doi:10.2147/CLEP.S103662
28. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data Resource Profile: The Danish National Prescription Registry. *Int J Epidemiol*. Published online October 27, 2016. doi:10.1093/ije/dyw213
29. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol*. 2015;7:449-490. doi:10.2147/CLEP.S91125
30. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. *Eur J Epidemiol*. 2014;29(8):541-549. doi:10.1007/s10654-014-9930-3
31. Henriksen DP, Rasmussen L, Hansen MR, Hallas J, Pottegård A. Comparison of the Five Danish Regions Regarding Demographic Characteristics, Healthcare Utilization, and Medication Use--A Descriptive Cross-Sectional Study. *PLoS One*. 2015;10(10):e0140197. doi:10.1371/journal.pone.0140197
32. Thygesen LC, Daasnes C, Thaulow I, Brønnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. *Scand J Public Health*. 2011;39(7 Suppl):12-16.
33. Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. *Neurology*. 2010;74(17):1346-1350. doi:10.1212/WNL.0b013e3181dad605
34. Hald S, Sloth C, Agger M, et al. The validity of intracerebral hemorrhage diagnoses in the Danish Patient Registry and the Danish Stroke Registry. *Clin Epidemiol*. 2020;12:1313-1326. doi:https://doi.org/10.2147/CLEP.S267583
35. Hald SM, Kring Sloth C, Hey SM, et al. Intracerebral hemorrhage: positive predictive value of diagnosis codes in two nationwide Danish registries. *Clin Epidemiol*. 2018;10:941-948. doi:10.2147/CLEP.S167576
36. Samarasekera N, Fonville A, Lerpiniere C, et al. Influence of intracerebral hemorrhage location on incidence, characteristics, and outcome: population-based study. *Stroke*. 2015;46(2):361-368. doi:10.1161/STROKEAHA.114.007953
37. Pasi M, Pongpitakmetha T, Charidimou A, et al. Cerebellar Microbleed Distribution Patterns and Cerebral Amyloid Angiopathy. *Stroke*. 2019;50(7):1727-1733. doi:10.1161/STROKEAHA.119.024843
38. Kremer PHC, Jolink WMT, Kappelle LJ, Algra A, Klijn CJM, SMART and ESPRIT Study Groups. Risk Factors for Lobar and Non-Lobar Intracerebral Hemorrhage in Patients with Vascular Disease. *PLoS One*. 2015;10(11):e0142338. doi:10.1371/journal.pone.0142338
39. Das AS, Regenhardt RW, Gokcal E, et al. Idiopathic primary intraventricular hemorrhage and cerebral small vessel disease. *Int J Stroke*. 2022;17(6):645-653. doi:10.1177/17474930211043957

40. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014;63(25 Pt B):2889-2934. doi:10.1016/j.jacc.2013.11.002
41. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *Am J Epidemiol*. 2003;158(9):915-920. doi:10.1093/aje/kwg231
42. Charidimou A, Schmitt A, Wilson D, et al. The Cerebral Haemorrhage Anatomical Rating Instrument (CHARTS): Development and assessment of reliability. *J Neurol Sci*. 2017;372:178-183. doi:10.1016/j.jns.2016.11.021
43. Kothari RU, Brott T, Broderick JP, et al. The ABCs of measuring intracerebral hemorrhage volumes. *Stroke*. 1996;27(8):1304-1305. doi:10.1161/01.str.27.8.1304
44. Graeb DA, Robertson WD, Lapointe JS, Nugent RA, Harrison PB. Computed tomographic diagnosis of intraventricular hemorrhage. Etiology and prognosis. *Radiology*. 1982;143(1):91-96. doi:10.1148/radiology.143.1.6977795
45. van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J. Grading white matter lesions on CT and MRI: a simple scale. *J Neurol Neurosurg Psychiatry*. 1990;53(12):1080-1083. doi:10.1136/jnnp.53.12.1080
46. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. *Ann Intern Med*. 2017;167(4):268-274. doi:10.7326/M16-2607
47. Roh D, Sun CH, Murthy S, et al. Hematoma Expansion Differences in Lobar and Deep Primary Intracerebral Hemorrhage. *Neurocrit Care*. 2019;31(1):40-45. doi:10.1007/s12028-018-00668-2
48. Witsch J, Bruce E, Meyers E, et al. Intraventricular hemorrhage expansion in patients with spontaneous intracerebral hemorrhage. *Neurology*. 2015;84(10):989-994. doi:10.1212/WNL.0000000000001344
49. Patrick AR, Shrank WH, Glynn RJ, et al. The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. *Value Health J Int Soc Pharmacoeconomics Outcomes Res*. 2011;14(4):513-520. doi:10.1016/j.jval.2010.10.033
50. Hald SM, Möller S, García Rodríguez LA, et al. Trends in Incidence of Intracerebral Hemorrhage and Association With Antithrombotic Drug Use in Denmark, 2005-2018. *JAMA Netw Open*. 2021;4(5):e218380. doi:10.1001/jamanetworkopen.2021.8380

Table 1. Characteristics of intracerebral hemorrhage cases with lobar and non-lobar hematoma location and their respective controls.

Characteristic, No. (%)	Lobar			Non-lobar		
	Cases (n=989)	Controls (n=39500)	Age & sex adj. OR (95% CI)	Cases (n=1175)	Controls (n=46755)	Age & sex adj. OR (95% CI)
Sex						
Male	473 (47.8)	18918 (47.9)	NA ¹	629 (53.5)	25005 (53.5)	NA ¹
Female	516 (52.2)	20582 (52.1)	NA ¹	546 (46.5)	21750 (46.5)	NA ¹
Age, mean (SD), years	76.3 (9.7)	76.3 (9.7)	NA ¹	75.1 (10.1)	75.1 (10.2)	NA ¹
Age, categories, years						
55-74	434 (43.9)	17387 (44.0)	NA ¹	585 (49.8)	23293 (49.8)	NA ¹
75-84	356 (36.0)	14166 (35.9)	NA ¹	368 (31.3)	14544 (31.1)	NA ¹
≥85	199 (20.1)	7947 (20.1)	NA ¹	222 (18.9)	8918 (19.1)	NA ¹
30-days fatality rate	317.0 (32.1)	NA ²	NA ¹	372.0 (31.7)	NA ²	NA ¹
Index year						
2009-2013	455 (46.0)	18141 (45.9)	NA ¹	518 (44.1)	20601 (44.1)	NA ¹
2014-2018	534 (54.0)	21359 (54.1)	NA ¹	657 (55.9)	26154 (55.9)	NA ¹
Comedication - current use ³						
Drugs with antihypertensive effect	549 (55.5)	23686 (60.0)	0.82 (0.72-0.94)	666 (56.7)	27069 (57.9)	0.95 (0.84-1.08)
Antiplatelet drugs	391 (39.5)	11014 (27.9)	1.75 (1.53-2.00)	401 (34.1)	12599 (26.9)	1.45 (1.27-1.64)
Oral anticoagulants	181 (18.3)	3652 (9.2)	2.31 (1.94-2.74)	257 (21.9)	4002 (8.6)	3.22 (2.78-3.74)
Non-aspirin nonsteroidal anti-inflammatory drugs	70 (7.1)	2336 (5.9)	1.21 (0.95-1.55)	106 (9.0)	2809 (6.0)	1.56 (1.27-1.91)
Selective serotonin reuptake inhibitors	144 (14.6)	3163 (8.0)	1.99 (1.66-2.39)	132 (11.2)	3558 (7.6)	1.56 (1.29-1.88)
Proton pump inhibitors	185 (18.7)	6732 (17.0)	1.12 (0.95-1.32)	218 (18.6)	7560 (16.2)	1.19 (1.02-1.38)
Oral corticosteroids	31 (3.1)	1373 (3.5)	0.90 (0.63-1.29)	34 (2.9)	1528 (3.3)	0.88 (0.62-1.25)
Hormone replacement therapy (women only)	44 (4.4)	1764 (4.5)	1.00 (0.73-1.36)	45 (3.8)	1927 (4.1)	0.93 (0.68-1.26)
Comorbidity						
Hypertension	658 (66.5)	26050 (65.9)	1.03 (0.90-1.19)	831 (70.7)	29772 (63.7)	1.44 (1.26-1.64)
Previous ischemic stroke	128 (12.9)	2049 (5.2)	2.76 (2.28-3.35)	179 (15.2)	2389 (5.1)	3.42 (2.89-4.04)
Diabetes	121 (12.2)	5140 (13.0)	0.93 (0.77-1.13)	162 (13.8)	6087 (13.0)	1.07 (0.91-1.27)
Chronic kidney disease	30 (3.0)	1009 (2.6)	1.20 (0.83-1.74)	42 (3.6)	1049 (2.2)	1.63 (1.19-2.23)

Chronic hepatic disease	30 (3.0)	526 (1.3)	2.33 (1.60-3.39)	35 (3.0)	570 (1.2)	2.50 (1.77-3.53)
Disorders indicative of high alcohol consumption	55 (5.6)	1319 (3.3)	1.73 (1.31-2.29)	89 (7.6)	1716 (3.7)	2.19 (1.75-2.75)
Chronic obstructive pulmonary disease	302 (30.5)	11812 (29.9)	1.03 (0.90-1.18)	382 (32.5)	13615 (29.1)	1.17 (1.04-1.33)
Ischemic heart disease	180 (18.2)	6833 (17.3)	1.06 (0.90-1.26)	191 (16.3)	7851 (16.8)	0.96 (0.82-1.13)
Peripheral artery disease	60 (6.1)	2061 (5.2)	1.18 (0.90-1.54)	81 (6.9)	2330 (5.0)	1.43 (1.13-1.80)
Congestive heart failure	87 (8.8)	2472 (6.3)	1.46 (1.16-1.83)	82 (7.0)	2811 (6.0)	1.18 (0.94-1.49)
Cancer (excl. non-melanoma skin)	180 (18.2)	6138 (15.5)	1.21 (1.03-1.43)	154 (13.1)	6733 (14.4)	0.90 (0.75-1.07)
*Atrial fibrillation	201 (20.3)	4658 (11.8)	1.98 (1.68-2.33)	256 (21.8)	5085 (10.9)	2.41 (2.08-2.79)
*Venous thromboembolism	54 (5.5)	1476 (3.7)	1.49 (1.13-1.98)	66 (5.6)	1716 (3.7)	1.57 (1.22-2.02)
*Mechanical heart valve	6 (0.6)	18 (0.0)	13.62 (5.36-34.63)	5 (0.4)	49 (0.1)	3.93 (1.56-9.90)
*Gastrointestinal bleed (upper, lower, or unspecified)	94 (9.5)	2633 (6.7)	1.48 (1.19-1.84)	100 (8.5)	2977 (6.4)	1.37 (1.11-1.69)
*Coagulopathy	5 (0.5)	92 (0.2)	2.02 (0.81-5.03)	7 (0.6)	115 (0.2)	2.44 (1.14-5.24)

*Only included for descriptive purposes, not included in models as covariates

¹Not applicable; by design cases and controls were matched on age, sex, and index year.

²Data only relevant for cases

³Current use of drug defined as most recent prescription supply covering index date or ending up to 30 days before index date

Table 2. Recency and duration of use of statins and risk of intracerebral hemorrhage – any location.

	Cases ¹ , no. (%) (n=2519)	Controls, no. (%) (n=100396)	OR ² (95% CI)	Adjusted OR ³ (95% CI)	E-value ⁴
Non-use of any statin ⁵	1584 (62.9)	65823 (65.6)	1 (reference)	1 (reference)	
Statin use					
Recency of use ⁶					
Current use	790 (31.4)	30075 (30.0)	1.10 (1.01-1.20)	0.83 (0.75-0.92)	1.70
Recent use	58 (2.3)	1874 (1.9)	1.29 (0.99-1.69)	1.00 (0.76-1.31)	1.00
Past use	87 (3.5)	2624 (2.6)	1.39 (1.11-1.73)	1.09 (0.87-1.37)*	1.40
Current use – duration					
<1 year	225 (8.9)	7512 (7.5)	1.26 (1.09-1.45)	0.95 (0.81-1.10)	1.29
≥1 year, <5 years	394 (15.6)	13957 (13.9)	1.18 (1.06-1.32)	0.88 (0.78-1.00)	1.53
≥5 years	171 (6.8)	8606 (8.6)	0.83 (0.71-0.98)	0.64 (0.54-0.76)**	2.50
Current use – intensity ⁷ of therapy & duration					
High	124 (4.9)	4418 (4.4)	1.16 (0.96-1.39)	0.99 (0.81-1.20)	1.11
<5 years	114 (4.5)	3855 (3.8)	1.17 (0.97-1.42)	1.00 (0.82-1.22)	1.00
≥5 years	10 (0.4)	563 (0.6)	0.72 (0.38-1.34)	0.61 (0.32-1.15)	2.66
Low-medium	666 (26.4)	25657 (25.6)	1.07 (0.98-1.18)	0.84 (0.76-0.93)	1.67
<5 years	525 (20.8)	18521 (18.4)	1.17 (1.05-1.29)	0.89 (0.80-1.00)	1.50
≥5 years	141 (5.6)	7136 (7.1)	0.81 (0.68-0.96)	0.64 (0.53-0.77)	2.50

P*-value <0.01 for test for trend; *P*-value <0.001 for test for trend

¹Includes all ICH, regardless of location, i.e., 989 lobar, 1,175 non-lobar, 275 large unclassifiable, 46 isolated intraventricular, 34 missing information on location.

²Adjusted for age, sex, and calendar period (year).

³Adjusted for age, sex, and calendar period and the following, based on register data: hypertension, previous ischemic stroke, diabetes, chronic renal insufficiency, chronic hepatic disease, coagulopathy, heart failure, ischemic heart disease, peripheral artery disease, cancer, high alcohol consumption, chronic obstructive pulmonary disease, use of oral anticoagulants, low-dose aspirin, clopidogrel, dipyridamole, nonsteroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors, hormone replacement therapy, or oral corticosteroid drugs.

⁴Metric for the potential impact of unmeasured confounding (VanderWeele and Ding, *Ann Int Med* 2017; 167: 268-74).

⁵No use of any statin in the 12-months before index-date.

⁶Based on the most recent treatment episode prior to the index date (date of diagnosis for cases and date of selection for controls), exposure was divided into current use (treatment episode ending 0-30 days before index date), recent use (31-90 days before index date), and past use (91-365 days before index date).

⁷High intensity: simvastatin 80mg/day; atorvastatin 20-80mg/day; rosuvastatin 10-40mg/day; Low-medium intensity: all other strengths.

Table 3. Duration of statin use and risk of intracerebral hemorrhage by hematoma location

Statin use	Lobar				E-value ³	Non-lobar				E-value ³
	Cases, no. (%) (n=989)	Controls, no. (%) (n=39500)	OR ¹ (95% CI)	Adjusted OR ² (95% CI)		Cases, no. (%) (n=1175)	Controls, no. (%) (n=46755)	OR ¹ (95% CI)	Adjusted OR ² (95% CI)	
Non-use of any statin ⁴	633 (64.0)	25820 (65.4)	1 (reference)	1 (reference)		746 (63.5)	30747 (65.8)	1 (reference)	1 (reference)	
Current statin use ⁵	305 (30.8)	11904 (30.1)	1.04 (0.91-1.20)	0.83 (0.70-0.98)	1.70	361 (30.7)	13930 (29.8)	1.08 (0.95-1.23)	0.84 (0.72-0.98)	1.67
Duration										
<1 year	81 (8.2)	2900 (7.3)	1.14 (0.90-1.44)	0.89 (0.69-1.14)	1.50	110 (9.4)	3558 (7.6)	1.29 (1.05-1.58)	1.00 (0.80-1.25)	1.00
≥1 year, <5 years	154 (15.6)	5530 (14.0)	1.14 (0.95-1.36)	0.89 (0.73-1.09)	1.50	177 (15.1)	6463 (13.8)	1.14 (0.96-1.35)	0.88 (0.73-1.06)	1.53
≥5 years	70 (7.1)	3474 (8.8)	0.82 (0.63-1.05)	0.67 (0.51-0.87)*	2.35	74 (6.3)	3909 (8.4)	0.79 (0.62-1.00)	0.62 (0.48-0.80)**	2.61
Intensity ⁶										
High	51 (5.2)	1721 (4.4)	1.20 (0.90-1.60)	1.06 (0.79-1.44)	1.31	58 (4.9)	2113 (4.5)	1.14 (0.87-1.50)	1.02 (0.77-1.35)	1.16
<5 years	NR	1498 (3.8)	1.22 (0.90-1.64)	1.09 (0.80-1.49)	1.40	53 (4.5)	1835 (3.9)	1.18 (0.89-1.56)	1.04 (0.78-1.39)	1.24
≥5 years	NR	223 (0.6)	0.72 (0.27-1.94)	NR		5 (0.4)	278 (0.6)	0.72 (0.30-1.76)	0.65 (0.26-1.59)	2.45
Low-medium	254 (25.7)	10183 (25.8)	1.00 (0.86-1.16)	0.82 (0.70-0.97)	1.74	303 (25.8)	11817 (25.3)	1.05 (0.92-1.21)	0.84 (0.72-0.98)	1.67
<5 years	196 (19.8)	7282 (18.4)	1.08 (0.92-1.27)	0.87 (0.72-1.03)	1.56	246 (20.9)	8609 (18.4)	1.16 (1.00-1.34)	0.91 (0.77-1.06)	1.43
≥5 years	58 (5.9)	2901 (7.3)	0.78 (0.60-1.03)	0.66 (0.49-0.87)	2.40	57 (4.9)	3208 (6.9)	0.74 (0.57-0.97)	0.59 (0.45-0.78)	2.78

*P-value 0.040 for trend; **P-value <0.001 for trend.

NR: Not reported (small numbers in ≥5 years statum) to preserve anonymity.

¹Adjusted for age, sex, and calendar period (year).

²Adjusted for age, sex, and calendar period and the following, based on register data: hypertension, previous ischemic stroke, diabetes, chronic renal insufficiency, chronic hepatic disease, coagulopathy, heart failure, ischemic heart disease, peripheral artery disease, cancer, high alcohol consumption, chronic obstructive pulmonary disease, use of oral anticoagulants, low-dose aspirin, clopidogrel, dipyridamole, nonsteroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors, hormone replacement therapy, or oral corticosteroid drugs.

³Metric for the potential impact of unmeasured confounding (VanderWeele and Ding, Ann Int Med 2017; 167: 268-74).

⁴No use of any statin in the 12-months before index-date.

⁵Most recent statin prescription supply covering index date or ending up to 30 days before index date.

⁶High intensity: simvastatin 80mg/day; atorvastatin 20-80mg/day; rosuvastatin 10-40mg/day; Low-medium intensity: all other strengths.

Table 4. Case-only analysis of current use of statins and risk of intracerebral hemorrhage in non-lobar vs lobar intracerebral hemorrhage.

Statin use	Hematoma location, No. (%)		OR ^{1,2} (95% CI)	Adjusted OR ^{1,3} (95% CI)	P-value ⁴
	Non lobar (n=1175)	Lobar (n=989)			
Non-use of any statin ⁵	746 (63.5)	633 (64.0)	1 (reference)	1 (reference)	
Current statin use ⁶	361 (30.7)	305 (30.8)	1.01 (0.83-1.21)	1.02 (0.82-1.27)	
Duration					
<1 year	110 (9.4)	81 (8.2)	1.14 (0.84-1.56)	1.16 (0.83-1.62)	
≥1 year, <5 years	177 (15.1)	154 (15.6)	0.98 (0.77-1.25)	1.01 (0.77-1.33)	
≥5 years	74 (6.3)	70 (7.1)	0.90 (0.63-1.27)	0.88 (0.61-1.27)	0.09
Intensity ⁷					
High	58 (4.9)	51 (5.2)	0.93 (0.63-1.38)	0.98 (0.65-1.48)	
<5 years	53 (4.5)	NR	0.94 (0.63-1.40)	0.98 (0.64-1.50)	
≥5 years	5 (0.4)	NR	1.06 (0.28-3.96)	NR	
Low-medium	303 (25.8)	254 (25.7)	1.02 (0.84-1.25)	1.03 (0.82-1.28)	
<5 years	246 (20.9)	196 (19.8)	1.07 (0.86-1.32)	1.08 (0.85-1.37)	
≥5 years	57 (4.9)	58 (5.9)	0.87 (0.59-1.27)	0.84 (0.56-1.24)	

NR: Not reported (small numbers in ≥5 years statum) to preserve anonymity.

¹Cases with intracerebral hemorrhage in lobar location are the reference group.

²Adjusted for age, sex, and calendar period (year).

³Adjusted for age, sex, and calendar period and the following, based on register data: hypertension, previous ischemic stroke, diabetes, chronic renal insufficiency, chronic hepatic disease, coagulopathy, heart failure, ischemic heart disease, peripheral artery disease, cancer, high alcohol consumption, chronic obstructive pulmonary disease, use of oral anticoagulants, low-dose aspirin, clopidogrel, dipyridamole, nonsteroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors, hormone replacement therapy, or oral corticosteroid drugs.

⁴Test for trend.

⁵No use of any statin in the 12-months before index-date.

⁶Most recent statin prescription supply covering index date or ending up to 30 days before index date.

⁷High intensity: simvastatin 80mg/day; atorvastatin 20-80mg/day; rosuvastatin 10-40mg/day; Low-medium intensity: all other strengths.

Table 5. Current use of statins and risk of location-specific ICH stratified by concurrent use of drugs with antihypertensive effects.

Concurrent medication use	Lobar					Non-lobar				
	Cases, no. (%)	Controls, no. (%)	OR ¹ (95% CI)	Adjusted OR ² (95% CI)	P-value ³	Cases, no. (%)	Controls, no. (%)	OR ¹ (95% CI)	Adjusted OR ² (95% CI)	P-value ³
Concurrent use of drugs with antihypertensive effects ⁴	(n=549)	(n=23686)				(n=666)	(n=27069)			
Non-use of any statin ⁵	285 (51.9)	12607 (53.2)	1 (reference)	1 (reference)		344 (51.7)	14189 (52.4)	1 (reference)	1 (reference)	
Current statin use ⁶	232 (42.3)	9838 (41.5)	1.02 (0.86-1.22)	0.97 (0.79-1.17)		274 (41.1)	11430 (42.2)	0.97 (0.82-1.14)	0.88 (0.74-1.05)	
Duration										
<5 years	178 (32.4)	6851 (28.9)	1.12 (0.93-1.36)	1.05 (0.85-1.29)		216 (32.4)	8073 (29.8)	1.08 (0.91-1.29)	0.98 (0.81-1.18)	
≥5 years	54 (9.8)	2987 (12.6)	0.79 (0.59-1.06)	0.75 (0.55-1.03)		58 (8.7)	3357 (12.4)	0.70 (0.53-0.93)	0.63 (0.47-0.85)	
No concurrent use of drugs with antihypertensive effects ⁴	(n=440)	(n=15814)				(n=509)	(n=19686)			
Non-use of any statin ⁵	348 (79.1)	13213 (83.6)	1 (reference)	1 (reference)		402 (79.0)	16558 (84.1)	1 (reference)	1 (reference)	
Current statin use ⁶	73 (16.6)	2066 (13.1)	1.35 (1.04-1.75)	1.12 (0.84-1.48)	0.39	87 (17.1)	2500 (12.7)	1.45 (1.14-1.84)	1.14 (0.88-1.48)	0.10
Duration										
<5 years	57 (13.0)	1579 (10.0)	1.39 (1.04-1.85)	1.16 (0.85-1.57)	0.58	71 (13.9)	1948 (9.9)	1.52 (1.18-1.97)	1.19 (0.90-1.58)	0.25
≥5 years	16 (3.6)	487 (3.1)	1.23 (0.74-2.05)	0.99 (0.58-1.68)	0.36	16 (3.1)	552 (2.8)	1.20 (0.72-1.99)	0.93 (0.55-1.59)	0.20

¹Adjusted for age, sex, and calendar period (year).

²Adjusted for age, sex, and calendar period and the following, based on register data: hypertension, previous ischemic stroke, diabetes, chronic renal insufficiency, chronic hepatic disease, coagulopathy, heart failure, ischemic heart disease, peripheral artery disease, cancer, high alcohol consumption, chronic obstructive pulmonary disease, use of oral anticoagulants, low-dose aspirin, clopidogrel, dipyridamole, nonsteroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors, hormone replacement therapy, or oral corticosteroid drugs.

³Wald test. Strength of association compared with corresponding measure with concurrent use of drugs with antihypertensive effects.

⁴Thiazides and non-loop diuretics, loop diuretics, beta-blockers, calcium channel blockers, ACE inhibitors, or angiotensin-II receptor blockers. Indication for drug use was not available to us and some of these drugs may have been used for indications other than hypertension.

⁵No use of any statin in the 12-months before index-date.

⁶Most recent statin prescription supply covering index date or ending up to 30 days before index date.

Table 6. Current use of statins and risk of location-specific ICH stratified by concurrent use of antithrombotic drugs.

Concurrent medication use	Lobar					Non-lobar				
	Cases, no. (%)	Controls, no. (%)	OR ¹ (95% CI)	Adjusted OR ² (95% CI)	P-value ³	Cases, no. (%)	Controls, no. (%)	OR ¹ (95% CI)	Adjusted OR ² (95% CI)	P-value ³
Concurrent use of oral anticoagulants ⁴	(n=181)	(n=3652)				(n=257)	(n=4002)			
Non-use of any statin ⁵	94 (51.9)	1931 (52.9)	1 (reference)	1 (reference)		126 (49.0)	2095 (52.3)	1 (reference)	1 (reference)	
Current statin use ⁶	71 (39.2)	1507 (41.3)	0.96 (0.69-1.32)	1.01 (0.71-1.45)		114 (44.4)	1673 (41.8)	1.11 (0.85-1.45)	1.07 (0.80-1.43)	
Duration										
<5 years	51 (28.2)	1025 (28.1)	1.00 (0.70-1.43)	1.04 (0.71-1.53)		85 (33.1)	1172 (29.3)	1.18 (0.88-1.58)	1.13 (0.83-1.54)	
≥5 years	20 (11.0)	482 (13.2)	0.86 (0.52-1.41)	0.95 (0.56-1.61)		29 (11.3)	501 (12.5)	0.95 (0.63-1.45)	0.90 (0.58-1.41)	
No concurrent use of oral anticoagulants ⁴	(n=808)	(n=35848)				(n=918)	(n=42753)			
Non-use of any statin ⁵	539 (66.7)	23889 (66.6)	1 (reference)	1 (reference)		620 (67.5)	28652 (67.0)	1 (reference)	1 (reference)	
Current statin use ⁶	234 (29.0)	10397 (29.0)	1.00 (0.85-1.16)	1.02 (0.85-1.22)	0.96	247 (26.9)	12257 (28.7)	0.94 (0.81-1.10)	0.92 (0.77-1.09)	0.081
Duration										
<5 years	184 (22.8)	7405 (20.7)	1.10 (0.93-1.30)	1.11 (0.92-1.35)	0.76	202 (22.0)	8849 (20.7)	1.07 (0.91-1.25)	1.02 (0.85-1.22)	0.22
≥5 years	50 (6.2)	2992 (8.3)	0.74 (0.55-0.99)	0.77 (0.56-1.05)	0.49	45 (4.9)	3408 (8.0)	0.62 (0.46-0.85)	0.62 (0.45-0.85)	0.025
Concurrent use of antiplatelet drugs ⁷	(n=391)	(n=11014)				(n=401)	(n=12599)			
Non-use of any statin ⁵	164 (41.9)	3960 (36.0)	1 (reference)	1 (reference)		167 (41.6)	4375 (34.7)	1 (reference)	1 (reference)	
Current statin use ⁶	204 (52.2)	6364 (57.8)	0.75 (0.60-0.93)	0.86 (0.69-1.09)		210 (52.4)	7364 (58.4)	0.68 (0.55-0.85)	0.77 (0.61-0.98)	
Duration										
<5 years	161 (41.2)	4471 (40.6)	0.84 (0.66-1.05)	0.94 (0.74-1.20)		174 (43.4)	5179 (41.1)	0.80 (0.63-1.00)	0.89 (0.70-1.13)	
≥5 years	43 (11.0)	1893 (17.2)	0.54 (0.38-0.76)	0.64 (0.45-0.92)		36 (9.0)	2185 (17.3)	0.40 (0.28-0.58)	0.47 (0.32-0.68)	
No concurrent use of antiplatelet drugs ⁷	(n=598)	(n=28486)				(n=774)	(n=34156)			
Non-use of any statin ⁵	469 (78.4)	21860 (76.7)	1 (reference)	1 (reference)		579 (74.8)	26372 (77.2)	1 (reference)	1 (reference)	
Current statin use ⁶	101 (16.9)	5540 (19.4)	0.84 (0.67-1.04)	0.79 (0.62-1.01)	0.61	151 (19.5)	6566 (19.2)	1.04 (0.87-1.25)	0.85 (0.69-1.04)	0.55
Duration										
<5 years	74 (12.4)	3959 (13.9)	0.86 (0.67-1.11)	0.81 (0.62-1.06)	0.41	113 (14.6)	4842 (14.2)	1.06 (0.86-1.30)	0.86 (0.69-1.08)	0.24
≥5 years	27 (4.5)	1581 (5.6)	0.78 (0.53-1.15)	0.75 (0.50-1.13)	0.56	38 (4.9)	1724 (5.0)	0.98 (0.70-1.37)	0.82 (0.57-1.16)	0.23

¹Adjusted for age, sex, and calendar period (year).

²Adjusted for age, sex, and calendar period and the following, based on register data: hypertension, previous ischemic stroke, diabetes, chronic renal insufficiency, chronic hepatic disease, coagulopathy, heart failure, ischemic heart disease, peripheral artery disease, cancer, high alcohol consumption, chronic obstructive pulmonary disease, use of oral anticoagulants, low-dose aspirin, clopidogrel, dipyridamole, nonsteroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors, hormone replacement therapy, or oral corticosteroid drugs.

³Wald test. Strength of association compared with corresponding measure with concurrent use of oral anticoagulant/antiplatelet drug.

⁴Vitamin K antagonist or direct oral anticoagulant.

⁵No use of any statin in the 12-months before index-date.

⁶Most recent statin prescription supply covering index date or ending up to 30 days before index date.

⁷Low-dose aspirin, or clopidogrel.

ACCEPTED

Table 7. Current use of statins and risk of location-specific ICH stratified by history of previous ischemic stroke.

	Lobar					Non-lobar				
	Cases, no. (%)	Controls, no. (%)	OR ¹ (95% CI)	Adjusted OR ² (95% CI)	P- value ³	Cases, no. (%)	Controls, no. (%)	OR ¹ (95% CI)	Adjusted OR ² (95% CI)	P- value ³
History of previous ischemic stroke ⁴	(n=128)	(n=2049)				(n=179)	(n=2389)			
Non-use of any statin ⁵	55 (43.0)	754 (36.8)	1 (reference)	1 (reference)		92 (51.4)	937 (39.2)	1 (reference)	1 (reference)	
Current statin use ⁶	58 (45.3)	1143 (55.8)	0.66 (0.45-0.98)	0.75 (0.49-1.13)		77 (43.0)	1262 (52.8)	0.55 (0.40-0.76)	0.63 (0.45-0.89)	
Duration										
<5 years	43 (33.6)	822 (40.1)	0.67 (0.44-1.02)	0.75 (0.48-1.16)		60 (33.5)	877 (36.7)	0.61 (0.43-0.87)	0.69 (0.48-1.00)	
≥5 years	15 (11.7)	321 (15.7)	0.63 (0.35-1.14)	0.74 (0.40-1.39)		17 (9.5)	385 (16.1)	0.41 (0.24-0.69)	0.48 (0.28-0.84)	
No history of previous ischemic stroke ⁴	(n=861)	(n=37451)				(n=996)	(n=44366)			
Non-use of any statin ⁵	578 (67.1)	25066 (66.9)	1 (reference)	1 (reference)		654 (65.7)	29810 (67.2)	1 (reference)	1 (reference)	
Current statin use ⁶	247 (28.7)	10761 (28.7)	0.99 (0.85-1.15)	1.06 (0.89-1.26)	0.12	284 (28.5)	12668 (28.6)	1.03 (0.89-1.18)	1.02 (0.87-1.20)	0.012
Duration										
<5 years	192 (22.3)	7608 (20.3)	1.09 (0.92-1.29)	1.15 (0.96-1.39)	0.072	227 (22.8)	9144 (20.6)	1.14 (0.97-1.32)	1.11 (0.93-1.32)	0.020
≥5 years	55 (6.4)	3153 (8.4)	0.75 (0.57-0.99)	0.81 (0.60-1.08)	0.79	57 (5.7)	3524 (7.9)	0.74 (0.56-0.97)	0.75 (0.57-1.01)	0.16

¹Adjusted for age, sex, and calendar period (year).

²Adjusted for age, sex, and calendar period and the following, based on register data: hypertension, previous ischemic stroke, diabetes, chronic renal insufficiency, chronic hepatic disease, coagulopathy, heart failure, ischemic heart disease, peripheral artery disease, cancer, high alcohol consumption, chronic obstructive pulmonary disease, use of oral anticoagulants, low-dose aspirin, clopidogrel, dipyridamole, nonsteroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors, hormone replacement therapy, or oral corticosteroid drugs.

³Wald test. Strength of association compared with corresponding measure with history of previous ischemic stroke.

⁴At any time before onset of first-ever ICH.

⁵No use of any statin in the 12-months before index-date.

⁶Most recent statin prescription supply covering index date or ending up to 30 days before index date.

Neurology[®]

Association Between Statin Use and Intracerebral Hemorrhage Location: A Nested Case-Control Registry Study

Nils Jensen Boe, Stine Munk Hald, Mie Micheelsen Jensen, et al.

Neurology published online December 7, 2022

DOI 10.1212/WNL.0000000000201664

This information is current as of December 7, 2022

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/early/2022/12/07/WNL.0000000000201664.full
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2022 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

